Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 236 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolism and Excretion Clear all

Conditions: Osteoporosis
Interventions: rhPTH(1-34), SB-751689 100 mg, SB-751689 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: San Diego, California • Daytona Beach, Florida • Port Orange, Florida + 2 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: 200 mg RV521/78 µCi [ 14C]-RV521.; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: [14C]-LX4211; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]BMS-986419; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: BMS-986166, Bisacodyl; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 2
Interventions: Tesaglitazar, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 21
States / cities: Pasadena, California • Washington D.C., District of Columbia • Gainesville, Florida + 18 more

Conditions: Healthy Volunteer
Interventions: [14C]CC-90001; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-STX-478; Drug
Lead sponsor: Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: [14C]-olinciguat; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]Ulonivirine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: BMS-986365, [14C] BMS-986365, [14C] BMS-986409 + BMS-986410, [14C] BMS-986410 + BMS-986409; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hepatic Insufficiency, Liver Diseases, Pharmacokinetics, Drug Metabolism
Interventions: Sevabertinib; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Healthy
Interventions: 14C-JNJ-42847922 40 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Male Subjects
Interventions: KW-6356; Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Gout, Hyperuricemia
Interventions: [14C] LC350189; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers, Healthy
Interventions: GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Thyroid Cancer
Interventions: Skin Biopsy; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus
Interventions: Rosuvastatin, Atorvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 29
States / cities: Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more

Conditions: Healthy Volunteer
Interventions: CC-220, [14C]; Drug · Radiation
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: OIC
Interventions: TD-1211 IV [C14], TD-1211 PO [C14]; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [¹⁴C]Enlicitide chloride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Fenebrutinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-brensocatib; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions: CC-223; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

Mass Balance Study of [14C]LC350189 in Healthy Volunteers

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Radiolabeled Study of CC-220 in Healthy Male Subjects

TD-1211 IV/Oral Mass Balance Study

A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects